Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.

ABSTRACT:

Introduction

Type-2 diabetes mellitus (T2DM) is a progressive disease, and many patients eventually require insulin therapy. This study examined real-world outcomes of switching basal insulin analogs among patients with T2DM.

Methods

Using two large United States administrative claims databases (IMPACT(®) and Humana(®)), this longitudinal retrospective study examined two cohorts of adult patients with T2DM. Previously on insulin glargine, Cohort 1 either continued insulin glargine (GLA-C) or switched to insulin detemir (DET-S), while Cohort 2 was previously on insulin detemir, and either continued insulin detemir (DET-C) or switched to insulin glargine (GLA-S). One-year follow-up treatment persistence and adherence, glycated hemoglobin (HbA1c), hypoglycemia events, healthcar

SUBMITTER: Wei W 

PROVIDER: S-EPMC4033813 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature